U.S. Auto Stock News

Pebblebrook Hotel Trust (PEB) has been quietly grinding higher this month, and that slow climb makes the stock worth a closer look. Recent returns hint at shifting sentiment around its hotel portfolio. See our latest analysis for Pebblebrook Hotel Trust. Zooming out, the 30 day share price return of 3.97% barely dents a negative year to date share price return of 13.26%, while the one year total shareholder return of 14.75% in the red shows that momentum is still rebuilding rather than fully...

Recent performance and what is driving interest First Hawaiian (FHB) has quietly put together a steady run, with the stock up about 7 % over the past month and 4 % in the past 3 months, drawing fresh attention from income focused bank investors. See our latest analysis for First Hawaiian. Zooming out, the stock’s roughly mid single digit year to date share price gain, alongside a 1 year total shareholder return of about 7 %, suggests momentum is quietly rebuilding as investors reassess risks...

We wouldn't blame Chesapeake Utilities Corporation ( NYSE:CPK ) shareholders if they were a little worried about the...

Key Insights The projected fair value for Scully Royalty is US$7.44 based on Dividend Discount Model Scully Royalty's...

The board of The Eastern Company ( NASDAQ:EML ) has announced that it will pay a dividend on the 13th of March, with...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

The board of Scholastic Corporation ( NASDAQ:SCHL ) has announced that it will pay a dividend on the 16th of March...

With its stock down 9.0% over the past three months, it is easy to disregard Meritage Homes (NYSE:MTH). However, the...

Franklin Resources, Inc. ( NYSE:BEN ) has announced that it will be increasing its periodic dividend on the 9th of...

Some Cencora, Inc. ( NYSE:COR ) shareholders may be a little concerned to see that the Senior VP, Lazarus Krikorian...

Halozyme Therapeutics recently received FDA approval for RYBREVANT FASPRO, co-formulated with its ENHANZE platform for advanced EGFR-mutated non-small cell lung cancer, and earlier this month secured a preliminary patent injunction in Germany against a rival subcutaneous product. Together with the addition of commercialization veteran Jim Lang to its board, these developments reinforce Halozyme’s positioning at the center of subcutaneous biologic drug delivery and IP protection. We’ll now...

Gold Royalty (NYSEAM:GROY) just closed a $90 million follow on equity offering at $4 per share, issuing 22.5 million new common shares. This represents a meaningful capital raise that immediately reshapes its growth runway. See our latest analysis for Gold Royalty. The equity raise caps a big year for the stock, with a roughly 230% year to date share price return and about 247% one year total shareholder return, signaling that momentum is clearly building as investors re rate its growth...

CareDx (CDNA) just moved to settle long running shareholder derivative lawsuits, tying the legal truce to a package of governance reforms that tighten oversight, disclosure practices, and compliance monitoring across the company. See our latest analysis for CareDx. The legal settlement and recent bylaw changes come as CareDx’s share price has climbed to about $19.45, with a 30 day share price return of 13.21% and a three year total shareholder return of 72.74%. This suggests improving...

In Q3 2025, Bilibili reported a net profit after earlier losses as stronger user engagement and higher advertising revenue lifted performance, while China’s Politburo shifted toward a moderately loose monetary policy to support domestic demand and technology investment for 2026. This combination of an earnings turnaround and a policy stance favoring digital consumption highlights how platform engagement and macro support may reinforce Bilibili’s role in China’s online entertainment...

Bread Financial Holdings (BFH) just saw Fitch assign a B minus rating to its new perpetual preferred stock, building on an earlier issuer upgrade to BB with a stable outlook that underscores improving credit quality. See our latest analysis for Bread Financial Holdings. The latest Fitch actions and a run of earnings beats seem to be feeding into sentiment, with the share price now at $78.0 and a strong 30 day share price return of 20.56 percent helping extend a 26.14 percent 1 year total...

In December 2025, Biohaven Ltd. reported at the ESMO Immuno-Oncology Congress that its Trop2-directed antibody drug conjugate BHV-1510, combined with Regeneron’s anti-PD-1 cemiplimab, showed encouraging safety and efficacy signals across several solid tumors, including non-small cell lung, endometrial, urothelial, and triple negative breast cancers. The early-stage data, including a confirmed objective response rate above half in evaluable patients and durable participation beyond six...

Analysts have just lifted earnings forecasts for ZTO Express (Cayman) (NYSE:ZTO) for this year and 2026, citing stronger parcel volumes, healthier revenue in core express delivery, and solid operational execution. See our latest analysis for ZTO Express (Cayman). Those upgraded earnings forecasts arrive after a solid run in the stock, with the 1 month share price return of 10.67 percent and year to date share price gain of 11.77 percent suggesting positive momentum. At the same time, the 3...

In mid-December 2025, Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer to apply its T-cell receptor discovery platform to rheumatoid arthritis and to license its extensive TCR–antigen binding dataset for Pfizer’s AI and machine learning-driven drug discovery efforts. The deals underscore the commercial potential of Adaptive’s immune repertoire data, with the rheumatoid arthritis collaboration alone carrying up to about US$890 million in possible milestones...

In recent days, multiple research firms including Truist Securities, Goldman Sachs, Citigroup, Barclays and Stifel reiterated positive views on Parker-Hannifin, signaling broad analyst confidence in the company’s operational and earnings outlook. This cluster of reaffirmed positive ratings and upgraded opinions effectively acts as a sentiment catalyst, spotlighting Parker-Hannifin as a preferred name among large-cap industrial and aerospace suppliers. Next, we’ll examine how this wave of...

Aptiv (NYSE:APTV) just expanded its automation ambitions by teaming up with Vecna Robotics to co develop autonomous mobile robots that aim to provide safer, more efficient material handling and a fresh avenue for long term growth. See our latest analysis for Aptiv. The Vecna Robotics tie up lands after a solid year to date share price return of roughly 30 percent, even though longer term total shareholder returns over three and five years remain negative. This suggests momentum is rebuilding...

Spyre Therapeutics (SYRE) just caught Wall Street’s eye, with firms like Mizuho and Citi initiating upbeat coverage that centers on its antibody pipeline for autoimmune and inflammatory diseases and upcoming clinical milestones. See our latest analysis for Spyre Therapeutics. Those upbeat notes are landing after a powerful run, with a 30 day share price return of roughly 38 percent and a 90 day share price return of around 118 percent. Meanwhile, the three year total shareholder return above...

Cipher Mining (CIFR) is suddenly on a lot more watchlists after locking in a multi billion dollar AI data center lease with Amazon Web Services, plus an expanded, Google backed Fluidstack hosting deal. See our latest analysis for Cipher Mining. Those AI infrastructure deals are arriving on the back of serious momentum, with a 30 day share price return of 14.56 percent and a year to date share price return of 235.61 percent. The three year total shareholder return of 2,901.85 percent shows how...

Relay Therapeutics, Inc. recently presented a subset analysis of interim data from its first-in-human ReDiscover trial, highlighting zovegalisib’s efficacy and tolerability in heavily pretreated HR+/HER2- advanced breast cancer patients at the 2025 San Antonio Breast Cancer Symposium. The data showed consistent progression-free survival and response rates across challenging subgroups, such as prior SERD exposure and ESR1-mutated tumors, reinforcing interest in this allosteric PI3Ka...